Yoav Doppelt joined Ofer Group in 1996 and is responsible for defining the vision and operational methodology of the company’s private equity and Hi-tech investments.
Today, Yoav serves as an active board member for Lumenis, Enzymotec, MGVS, and Yozma Venture Capital ($170M under management) and is driving a range of investments within the private equity and hi-tech arena.
In addition, Yoav has successfully led several exit deals and has extensive experience in exit management.
Yoav has well-seasoned, hands-on experience with portfolio companies including MGVS (cell therapy), Naopass (Medical devices) and Coreflow (Capital Equipment) and has served as an active chairman for Enzymotec, health food ingredients.
Previously, Yoav held finance and managerial positions within Ofer Group, including director in Tower Semiconductors (Nasdaq: TSEM) and IMI – Israel Chemical's R&D Institution.
Yoav holds a BSc from the faculty of Industrial Management at the Technion – Israel Institute of Technology, as well as an MBA from Haifa University, Israel. | 
Team
